Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Karyopharm Therapeutics (KPTI) over the last 6 years, with Q1 2025 value amounting to $8470.0.

  • Karyopharm Therapeutics' Shares Outstanding (Diluted Average) rose 1000.0% to $8470.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $8470.0, marking a year-over-year increase of 1000.0%. This contributed to the annual value of $114.2 million for FY2023, which is 3951.34% up from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Shares Outstanding (Diluted Average) of $8470.0 as of Q1 2025, which was up 1000.0% from $154.4 million recorded in Q2 2024.
  • In the past 5 years, Karyopharm Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $154.4 million in Q2 2024 and a low of $7700.0 during Q1 2024
  • Its 5-year average for Shares Outstanding (Diluted Average) is $82.6 million, with a median of $79.9 million in 2022.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 4629.5% in 2023, and later plummeted by 9999.32% in 2024.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Shares Outstanding (Diluted Average) stood at $75.2 million in 2021, then grew by 8.84% to $81.9 million in 2022, then surged by 39.51% to $114.2 million in 2023, then soared by 35.2% to $154.4 million in 2024, then plummeted by 99.99% to $8470.0 in 2025.
  • Its last three reported values are $8470.0 in Q1 2025, $154.4 million for Q2 2024, and $7700.0 during Q1 2024.